Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5f2d89a8c9d985b85a5d6512df76351 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-335 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-357 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1825 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-357 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-047 |
filingDate |
2008-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf9d9cb4bef7e7efa09c48a786b9e981 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ca712718d55c8c6a6f6dd82a842336b |
publicationDate |
2014-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20140074988-A |
titleOfInvention |
Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury |
abstract |
The present invention provides the use of a protein kinase activator or a nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factor to treat a stroke. In particular, the present invention relates to a method of identifying a subject suffering from stroke and a method of screening a subject for a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier, Or a pharmaceutically acceptable salt thereof, in an amount effective to treat the above conditions. |
priorityDate |
2007-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |